Conditions · Pancreatic cancer
Pancreatic cancer — frontier options in Texas
30 open options
- TRIALPHASE2RECRUITING
EUS-RFA PANCARDINAL-1 Trial
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) · Neoadjuvant Chemotherapy (NAC) — 1 site
- TRIALPHASE1RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NT-112: Autologous, engineered T Cells targeting KRAS G12D · AZD0240: Autologous, engineered T Cells targeting KRAS G12D — 18 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AMXI-5001:Dose Escalation Phase I · AMXI-5001:Dose Expansion Phase II — 4 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib · Oxaliplatin · Leucovorin — 48 sites
- TRIALPHASE1 / PHASE2RECRUITING
A 2-part Phase 1/2 Open-label Trial on ODM-212
ODM-212 · Ipilimumab and nivolumab · Gemcitabine and nab-paclitaxel — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Evofosfamide · Zalifrelimab · Balstilimab — 1 site
- TRIALPHASE1RECRUITING
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
XL309 · Olaparib — 16 sites
- TRIALNARECRUITING
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
high dose rate brachytherapy · high dose rate brachytherapy — 1 site
- TRIALPHASE2RECRUITING
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AZD0901 · 5-Fluorouracil · Leucovorin — 52 sites
- TRIALPHASE1RECRUITING
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RMC-9805 · RMC-6236 — 17 sites
- TRIALPHASE1RECRUITING
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
AVA6103 — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Elironrasib · Daraxonrasib — 55 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
daraxonrasib — 257 sites
- TRIALPHASE1RECRUITING
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
DSB2455 — 18 sites
- TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
- TRIALPHASE3RECRUITING
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib · GnP · mGnP — 38 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
VS-7375 · Cetuximab · Carboplatin + Pemetrexed + Pembrolizumab — 14 sites
- TRIALPHASE1RECRUITING
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDE892 · IDE397 — 17 sites
- TRIALPHASE1NOT_YET_RECRUITING
IKS04 Regimen in Advanced Solid Tumors That Express CA242
IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
MT-4561 — 6 sites
- TRIALPHASE1RECRUITING
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RMC-5127 · daraxonrasib · cetuximab — 9 sites
- TRIALPHASE1 / PHASE2RECRUITING
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
MDX2001 — 6 sites
- TRIALNANOT_YET_RECRUITING
Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
intermittent fasting — 1 site
- TRIALPHASE2RECRUITING
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Pembrolizumab · Folfirinox — 3 sites
- TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
- TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 — 6 sites
- TRIALPHASE1 / PHASE2RECRUITING
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Mavrostobart (PT199) · Tislelizumab · Gemcitabine + nab-Paclitaxel — 6 sites
- TRIALPHASE1RECRUITING
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
STRO-004 · Pembrolizumab — 9 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.